These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23977426)

  • 1. Exploitation of adaptive evolution in glioma treatment.
    Cordner R; Black KL; Wheeler CJ
    CNS Oncol; 2013 Mar; 2(2):171-9. PubMed ID: 23977426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Rare clinical form of glioblastoma multiforme].
    Ejma M; Waliszewska-Prosół M; Hofman A; Bladowska J; Zub LW; Podemski R
    Postepy Hig Med Dosw (Online); 2014 Mar; 68():316-24. PubMed ID: 24864082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance.
    Squatrito M; Holland EC
    Cancer Res; 2011 Sep; 71(18):5945-9. PubMed ID: 21917735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma multiforme: a review of where we have been and where we are going.
    Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma antigen discovery--foundations for immunotherapy.
    Azad TD; Razavi SM; Jin B; Lee K; Li G
    J Neurooncol; 2015 Jul; 123(3):347-58. PubMed ID: 26045361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas.
    Janelidze S; Bexell D; Badn W; Darabi A; Smith KE; Fritzell S; Gunnarsson S; Milos P; Bengzon J; Salford LG; Siesjö P; Visse E
    J Immunother; 2009; 32(6):593-601. PubMed ID: 19483650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium.
    Kim ES; Kim JE; Patel MA; Mangraviti A; Ruzevick J; Lim M
    J Immunol Res; 2016; 2016():4683607. PubMed ID: 26881264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of TRAIL and irradiation in elimination of glioblastoma stem-like cells.
    Liu J; Gao Q; Xie T; Liu Y; Luo L; Xu C; Shen L; Wan F; Lei T; Ye F
    Clin Exp Med; 2018 Aug; 18(3):399-411. PubMed ID: 29777390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
    Goetz C; Gromeier M
    Cytokine Growth Factor Rev; 2010; 21(2-3):197-203. PubMed ID: 20299272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013.
    Pietschmann S; von Bueren AO; Henke G; Kerber MJ; Kortmann RD; Müller K
    J Neurooncol; 2014 Dec; 120(3):451-7. PubMed ID: 25160993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How immunotherapies are targeting the glioblastoma immune environment.
    Felthun J; Reddy R; McDonald KL
    J Clin Neurosci; 2018 Jan; 47():20-27. PubMed ID: 29042147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational research in glioblastoma multiforme: molecular criteria for patient selection.
    Rosell R; de Las Peñas R; Balaña C; Santarpia M; Salazar F; de Aguirre I; Reguart N; Villa S; Wei J; Ramirez JL; Molina MA; Ramon y Cajal S; Jablons D; Taron M
    Future Oncol; 2008 Apr; 4(2):219-28. PubMed ID: 18407735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
    Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
    PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
    Choi BD; Curry WT; Carter BS; Maus MV
    Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
    Samaha H; El Naggar S; Ahmed N
    Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
    [No Abstract]   [Full Text] [Related]  

  • 18. Chromosome 1p and 19q deletions in glioblastoma multiforme.
    Kaneshiro D; Kobayashi T; Chao ST; Suh J; Prayson RA
    Appl Immunohistochem Mol Morphol; 2009 Dec; 17(6):512-6. PubMed ID: 19602970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
    Wildes TJ; Grippin A; Dyson KA; Wummer BM; Damiani DJ; Abraham RS; Flores CT; Mitchell DA
    Clin Cancer Res; 2018 Aug; 24(16):3955-3966. PubMed ID: 29712687
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
    Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
    Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.